18 Feb 2011

Neglected Disease Research and Development: Is the Global Financial Crisis Changing R&D?

The third G-FINDER survey reports on 2009 global investment into research and development (R&D) of new products for neglected diseases, and identifies early trends and patterns across the three years of global G-FINDER data. It covers:

  • 31 neglected diseases
  • 134 product areas for these diseases, including drugs, vaccines, diagnostics, microbicides and vector control products
  • Platform technologies (e.g. adjuvants, delivery technologies, diagnostic platforms)
  • All types of product-related R&D, including basic research, discovery and preclinical, clinical development, Phase IV and pharmacovigilance studies, and baseline epidemiological studies.

Building on the past two years, survey scope was further expanded this year in order to capture the fullest picture of global investment into neglected disease R&D, with private sector organisations in Brazil and India, and public funders in Ghana, Colombia and Thailand included in the survey for the first time. In all, 847 organisations were surveyed in 2009, a 5% increase on 2008. The number of organisations completing the survey rose to 218, also a 5% increase on 2008, with 100% of top funders providing their 2009 data.

Visit the Policy Cures website to learn more about the G-Finder reports.